Ceregate

CereGate operates at the intersection of medical devices, neuroscience, software, and brain-computer interfaces. Its stated differentiation is a hardware-agnostic software layer intended to work with existing deep-brain-stimulation and spinal-cord-stimulation implants, potentially reducing the need for additional surgery compared with approaches that require a new proprietary implant system. The company is pursuing clinical use cases such as Freezing of Gait in Parkinson’s disease, vestibular balance disorders, and sensory restoration, while also describing higher-bandwidth neural communication and future applications in hearing and vision. The available similarity results do not provide a reliable set of distinct peer companies; they repeat CereGate itself. As a result, direct competitor benchmarking is limited. CereGate appears more focused on software-enabled neuromodulation and implant interoperability than on building a complete implant hardware stack.

CereGate’s trajectory shows a progression from company formation in 2019 to seed financing on Jan 24, 2020, a Series A on Sep 3, 2020, and a convertible note on Jan 12, 2022. Technically, the company has expanded its scope from a computer-brain-interface concept into a modular platform for existing spinal-cord and deep-brain-stimulation implants. Its patent portfolio includes filings on neuronal communication, closed-loop autocalibration, side-effect reduction, behavior modification, and balance or auditory interfaces. Website materials cite testing involving more than 85 participants, suggesting movement beyond laboratory concepts toward clinical validation. The company’s employee-size indicator remains in the 11-to-50 range, while its public hiring message seeks expertise in neuroscience, neuromodulation, imaging, and brain-computer interfaces. The next measurable inflection points would be regulatory progress, additional clinical results, commercial partnerships, and new financing; none is publicly quantified in the current profile.